Press Room > November 2007 Archives

« October 2007 | Main | December 2007 »

Bioponic Phytoceuticals CEO Issues Letter to Shareholders

MAUI, Hawaii, Nov. 29 /PRNewswire-FirstCall/ -- Bioponic Phytoceuticals,Inc. (Pink Sheets: BPYT)BPI Logo ("Bioponic"), an innovative provider of naturalproducts and patented technology serving the Complementary AlternativeMedicine (CAM) and nutraceutical markets, issued today a letter toshareholders from CEO and Chairman Steven M. Schorr to discuss the Company'smaterial developments during 2007.

Dear Shareholders:

I have great enthusiasm about Bioponic's achievements to-date, and theoutlook for the natural products and phytochemical production industry as awhole. Pharmaceuticals derived from plants account for over $10 Billion insales in the U.S. alone, and demand for plant-derived medicinals is on therise worldwide. By 2010, global sales of nutritional preparations and naturalmedicine will top nearly $200 Billion. Bioponic has over 94 proprietaryproducts in commercial production through our unique BioresonantPhytotherapeutic(TM) formulas and our proprietary Airponic Growth System thatenables the in-house production of the highest quality health and wellnessproducts.

  --  This month, we launched Curemisinin(TM), an all-natural
        artemisinin-based treatment for malaria. Alternative anti-malaria
        medicines are in dire need in places like Africa, where every 30
        seconds a child dies of the disease. According to the World Health
        Organization (WHO), "The inappropriate use of anti-malarial drugs in
        the past century contributed to widespread resistance in the malaria
        parasite to drugs such as chloroquine, leading to rising rates of
        sickness and death. Over the past decade, a new group of
        antimalarials-- known as artemisinin-based combination
        therapies -- has brought new hope in the fight against malaria."
        (http://www.who.int/features/factfiles/malaria/en/index.html)
    --  Representatives from the American Friends of Guinea began distributing
        Curemisinin to clinics in Conakry, the capital city of Guinea, Africa.
        These human clinical trials will record the efficacy of Curemisinin,
        an important step toward partnering with WHO and other organizations
        that can aide Bioponic in bringing Curemisinin into countries where it
        is needed most.
    --  Our flagship product Flight Spray® is on the heels of a mass-market
        launch into national retail outlets, including major health food
        chains, top-name pharmacies and drug stores, beginning in the first
        quarter of 2008.
    --  Our Master Broker for the Western U.S., Active Sales and Marketing of
        Southern California, will expand our retail channels for six of our
        core product lines to 1,000 or more of the nation's top health food
        stores in the Western region. We anticipate this agreement can add
        $1.5 Million in sales to Bioponic in 2008.
    --  This month also marked the launch of our first product suite geared
        specifically for newborns and infants called Gentle Mother(TM). Gentle
        Mother, a suite of five products that treat common ailments of babies,
        is available for purchase online and will be rolled out to 1,000 or
        more national retail chains beginning in 2008.
    --  Entered into a $500,000 exclusive production and sales agreement with
        Malie, Inc. of Kauai, Hawaii to manufacture Malie's new Facial Tonic
        product line using Bioponic's proprietary ingredients and
        formulations.
    --  Received an initial order from Singapore-based Muji Global Sourcing
        Pte. Ltd. ("Muji"), who will be selling several Bioponic product lines
        throughout its established territories in Asia.
    --  Developed Curecumin(TM), a Bioresonant Phytotherapeutic(TM) formula
        designed to treat Alzheimer's Disease and the five leading forms of
        cancer (breast, colon, lung, prostate and skin cancers)
    --  Continue to develop our portfolio of intellectual properties with the
        acquisition of trademarks for our branded products and patent pending
        status for our Bioresonant Phytotherapeutic technology.

Continue reading "Bioponic Phytoceuticals CEO Issues Letter to Shareholders" »

Bioponic Phytoceuticals Introduces All Natural Baby Product Suite 'Gentle Mother'

MAUI, Hawaii, Nov. 19 /PRNewswire-FirstCall/ -- Bioponic Phytoceuticals, Inc. (Pink Sheets: BPYT - News;Gentle Mother Logo

"Bioponic"), an innovative provider of natural products and patented technology serving the Complementary Alternative Medicine (CAM) and nutraceutical markets, announced the launch of its first product suite geared specifically for newborns and infants called "Gentle Mother(TM)". Gentle Mother is comprised of five, all natural herbal remedies based on the Company's proprietary Bioresonant Phytotherapeutic(TM) formulations with easy-to-use, liquid spray delivery systems. Each product is a gentle water-based formula designed to soothe and treat common, recurring ailments such as diaper rash, teething, nasal congestion, as well as aide in digestion and sleep.

"Many parents are turning towards all natural baby formulations to avoid additives and unwanted preservatives that may cause side effects or can be detrimental to their children's health, especially over extended periods of use. Consumers are more health conscious, environmentally aware and receptive to alternative remedies than ever before. Demand for natural baby products is dramatically on the rise, and a number of the world's leading brands and grocers are clearing shelf space for 'green' baby product lines. For instance, one leading food chain has tripled the space allotted to natural baby products in just the last five years," said Steven M. Schorr, chairman and CEO of Bioponic.

Gentle Mother is currently available for purchase at http://www.bioponic.com and will soon be available in leading health food stores. According to Schorr, "We are very enthusiastic to begin marketing Gentle Mother worldwide, and in early 2008 we plan to make the entire suite available in over 1,000 health food stores. We have the distribution agreements in place to take several of our products to a national scale, and Gentle Mother is a very promising addition in our product line-up for 2008."

 

Continue reading "Bioponic Phytoceuticals Introduces All Natural Baby Product Suite 'Gentle Mother'" »

Guineans get free malaria drugs

afrol News, 16 November -Afrol Logo

A new malaria treatment [Curemisinin] is being disseminated free-of-charge in clinics located in the Guinean capital Conakry, Bioponic Phytoceuticals announced.

Curemisinin (TM), an all-natural anti-malaria product that is based on three proven effective anti-malaria herbs: Artemesia, Turmeric and Cinchona Bark, is launched by Bioponic Phytoceuticals.

Bioponic is focused on the production of natural products that are used to promote health and well-being and its binary product comprises a nasal spray [Curemisinin A] with an oral spray [Curemisinin B] to treat malaria in the quickest, most effective manner.

The efficacy of Curemisinin will be recorded, and provide valuable data over the next several weeks on the product's ability to treat malaria in humans.

The Chairman and CEO of Bioponic, Steven Schorr said, "Curemisinin's use of a nasal delivery system allows the bioresonant liquid remedy to be delivered directly to the brain via the nasal membrane. This may have a significant impact on cerebral malaria, a condition primarily affecting children, who die within 24 to 7 hours without treatment.

Biponic not only hopes to stop the track of cerebral malaria, but potentially help bring down the cost of treatment and increase the efficacy of treatments for all types of malaria, especially resistant strains of the disease."

Caused by a blood parasite transmitted by mosquitoes, malaria has become the number one killer disease in sub-Saharan Africa. Every year, malaria kills more than a million people worldwide, majority of its victims being African children.

As evolving pathogens develop widespread resistance to over-prescribed antibiotics, anti-virals and antimalarial drugs, the use of natural medicines is being recommended for their proven efficacy in the treatment of vast malaria problem.

BPYT: Launch of Curemisinin(TM) All-Natural Anti-Malaria Product

Ridgeland, MS, NOV 13, 2007 (EventX/Knobias.com via COMTEX) -- By Fain Hughes, fhughes@knobias.comKnobias logo

Bioponic Phytoceuticals, Inc. (BPYT) announced the launch of Curemisinin(TM), an all-natural anti-malaria product that is based on three proven effective anti-malaria herbs (Artemesia, Turmeric and Cinchona Bark) extracted through the Company's proprietary extraction/distillation technologies. This binary product comprises a nasal spray (Curemisinin A) with an oral spray (Curemisinin B) to treat malaria.

Continue reading "BPYT: Launch of Curemisinin(TM) All-Natural Anti-Malaria Product" »

Bioponic Phytoceuticals Launches Curemisinin for the Treatment of Malaria in Guinea, Africa

MAUI, Hawaii, Nov. 13 /PRNewswire-FirstCall/ -- Bioponic Phytoceuticals, Inc. (Pink Sheets: BPYT - News;Curemisinin Bot

"Bioponic"), an innovative provider of natural products and patented technology serving the Complementary Alternative Medicine (CAM) and nutraceutical markets, announced today the launch of Curemisinin(TM), an all-natural anti-malaria product that is based on three proven effective anti-malaria herbs: Artemesia, Turmeric and Cinchona Bark, uniquely extracted through the Company's proprietary extraction/distillation technologies. This binary product comprises a nasal spray (Curemisinin A) with an oral spray (Curemisinin B) to treat malaria in the quickest, most effective manner.

Malaria is a disease caused by a blood parasite transmitted by mosquitoes, and the number one killer in sub-Saharan Africa, killing more than a million people worldwide, every year. The majority of those who die from malaria are African children, according to the Centers for Disease Control. Through Bioponic's international alliance with Hyperdynamics Corp, Curemisinin is currently being disseminated free-of-charge in clinics located in the capital city of Guinea, Africa. The efficacy of Bioponic's Curemisinin will be recorded, and provide valuable data over the next several weeks on the product's ability to treat malaria in humans.

Bioponic's Chairman and CEO Steven M. Schorr remarked, "Curemisinin's use of a nasal delivery system allows the bioresonant liquid remedy to be delivered directly to the brain via the nasal membrane. This may have a significant impact on Cerebral Malaria, a condition primarily affecting children, who die within 24 to 72 hours without treatment. Bioponic not only hopes to stop the track of cerebral malaria, but potentially help bring down the cost of treatment and increase the efficacy of treatments for all types of malaria, especially resistant strains of the disease."

 

Continue reading "Bioponic Phytoceuticals Launches Curemisinin for the Treatment of Malaria in Guinea, Africa" »

BPYT: To Launch Mass Roll-out of Nasal Hydration Product Flight Spray®

10:31 a.m.  11/01/2007    Provided by Knobias.comKnb Logo

Ridgeland, MS, NOV 01, 2007 (EventX/Knobias.com via COMTEX) -- By Fain Hughes, fhughes@knobias.com

Bioponic Phytoceuticals, Inc. (BPYT) is preparing to launch a national roll-out of its nasal hydration product Flight Spray(R) to mass market retailers and top-name pharmacy and drug store chains beginning in the first quarter of 2008. Flight Spray is the first all-natural nasal hydration spray formulated especially for airline travel. The 1oz bottle of Flight spray is an approved on-board liquid, which eliminates consumer concerns over traveling regulations.

Flight Spray is currently sold in travel-related retail stores and via web sites such as Magellens.com, TravelSmith.com and Drugstore.com, and on the Company-owned FlightSpray.com.

Bioponic Phytoceuticals Plans to Bring Flight Spray Product to Mass Market Retailers Nationwide Beginning in Q1 2008

MAUI, Hawaii, Nov. 1 /PRNewswire-FirstCall/ -- FS Box

Bioponic Phytoceuticals, Inc. ("Bioponic" or "the Company") (OTC: BPYT - News) today announced that it is preparing to launch a national roll-out of its nasal hydration product Flight Spray® to mass market retailers and top-name pharmacy and drug store chains beginning in the first quarter of 2008.

Flight Spray has sold over 50,000 units since its initial launch in April 2005. "We are preparing for a mass market push that has the potential to exponentially increase sales of Flight Spray during 2008," said Steven M. Schorr, chairman & CEO of Bioponic. "The early buzz on Flight Spray was that it was the next Airborne. Good Morning America and ABC Health News were among the first national media outlets to favorably compare it to Airborne. Considering Airborne sold over $100 million last year, Flight Spray could achieve similar sales success given the expansion we have planned in significantly large retail markets."

Flight Spray is currently sold in travel-related retail stores and via web sites such as Magellens.com, TravelSmith.com and Drugstore.com, and on the Company-owned FlightSpray.com. Flight Spray is also available on Amazon.com, along with 85 other Bioponic Phytoceuticals products, and at AllNaturalMerchandise.com. In Australia, Flight Spray is sold on GlobalTravelProducts.com and in the U.K. and Europe at Vocal-care.com. Flight Spray comes in a 1oz. (30ml) and .5oz (15ml) pump spray bottle and is now shelf ready in a display box.

Continue reading "Bioponic Phytoceuticals Plans to Bring Flight Spray Product to Mass Market Retailers Nationwide Beginning in Q1 2008" »